Insider · CIK 0001579872
Mahesh V. Patel
Files at LPCN (Lipocine Inc.). First filing Apr 2, 2026, latest Apr 6, 2026.
In brief
Mahesh V. Patel files SEC Form 4 as CEO and director at LPCN (Lipocine Inc.). Since Apr 2, 2026, Mahesh V. Patel has reported 2 open-market buys worth $101k and 0 open-market sells worth $0, the latest filed on Apr 6, 2026.
A track record needs three past buys with six months of prices behind them; Mahesh V. Patel has 0, so none is measured yet.
The newest scored trade: bought $51k of LPCN on Apr 6, 2026, filed Apr 6, 2026, scored 66 (notable). In the last 12 months: 2 buys worth $101k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
LPCN: Lipocine Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 66Notable | Lipocine Inc. | $51k 25,000 shares | +18% | 0% from low-83% from high | |
| 64Notable | Lipocine Inc. | $51k 25,000 shares | +23% | 0% from low-82% from high |
Transactions
Every row this insider has filed, 6 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 29, 2026 | LPCN Lipocine Inc. | AGrant or award Stock Option (Right to Buy)derivative | +52,781 | $2.49 | $131k | 227,214 | Jun 30, 2026 |
| Apr 6, 2026 | LPCN Lipocine Inc. | POpen-market purchase Common stock | +25,000 | $2.03 | $51k | 160,679 | Apr 6, 2026 |
| Apr 2, 2026 | LPCN Lipocine Inc. | POpen-market purchase Common stock | +25,000 | $2.02 | $51k | 135,679 | Apr 2, 2026 |
| Jan 2, 2026 | LPCN Lipocine Inc. | AGrant or award Stock Option (Right to Buy)derivative | +25,000 | $8.00 | $200k | 182,668 | Jan 5, 2026 |
| Dec 18, 2025 | LPCN Lipocine Inc. | AGrant or award Stock Option (Right to Buy)derivative | +8,629 | $4.20 | $36k | 157,668 | Dec 19, 2025 |
| Dec 23, 2024 | LPCN Lipocine Inc. | AGrant or award Stock Option (Right to Buy)derivative | +26,691 | $4.80 | $128k | 149,039 | Dec 30, 2024 |
Questions about Mahesh V. Patel
Answered from the filings on this page, as of the latest one.
Is Mahesh V. Patel buying or selling?
In the last 12 months Mahesh V. Patel reported 2 open-market buys worth $101k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $51k of LPCN on Apr 6, 2026. Grants, option exercises and tax withholding are not counted.
How did Mahesh V. Patel's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Mahesh V. Patel has 0.
Where does Mahesh V. Patel file Form 4?
Mahesh V. Patel has filed Form 4 at LPCN (Lipocine Inc.) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.